The FDA has approved a new drug called Donanemab that has shown to slow down the progression of Alzheimer's disease in clinical trials.
This is the second drug approved by the FDA to treat early stage Alzheimer's, following the approval of Leqembi last year.
Donanemab, developed by Eli Lilly, targets amyloid protein deposits in the brain, which are a key indicator of Alzheimer's.
While not a cure, this drug offers hope for slowing down the decline in cognitive function and functional independence experienced by individuals with Alzheimer's.
